Xspray Pharma announced the appointment of Edward P. Jordan as chief commercial officer. Mr. Jordan will lead the US product launch and commercialization of DasynocTM with an anticipated launch in September 2024, subject to FDA approval. Assuming his new role effective September 15, Mr. Jordan transitions from his recent position as Chief Commercial Officer at Humanigen Inc. In this pivotal role, Mr. Jordan will team up with Xspray Pharma's US commercialization partner, Eversana.

Together, they'll prepare for the successful commercialization of DasynocTM where he will leverage a solid history of collaborating with Eversana. Mr. Jordan's will also helm the commercial introduction of other products in Xspray Pharma's pipeline, capitalizing on the company's patented amorphous technology platform while building the US infrastructure.